[Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO]

Urologe A. 2017 Nov;56(11):1471-1472. doi: 10.1007/s00120-017-0519-9.
[Article in German]
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Humans
  • Male
  • Prostatic Neoplasms, Castration-Resistant*
  • Taxoids

Substances

  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • pembrolizumab